Docetaxel 80mg Injection

Docetaxel 80mg Injection is a highly potent, semi-synthetic antineoplastic agent belonging to the taxane class of chemotherapy drugs, specifically formulated for the systemic treatment of various aggressive malignancies. Derived from the needles of the European yew tree (Taxus baccata), Docetaxel 80mg Injection functions as a sophisticated microtubule inhibitor. Unlike many cytotoxic agents that damage DNA directly, this medication works by targeting the cell’s internal skeleton. It promotes the assembly of tubulin into stable microtubules and, crucially, inhibits their disassembly. This “freezing” of the microtubule network prevents the cell from organizing the mitotic spindle required for cell division. Consequently, the cancer cells are arrested in the G2/M phase of the cell cycle and undergo apoptosis (programmed cell death). Discover how this professional pharmaceutical intervention provides the ultimate clinical advantage for patients with advanced or metastatic disease, offering a powerful and proven method to halt tumor progression and extend survival through high-precision cytoskeletal stabilization.

Indications / Uses of Docetaxel 80mg Injection

Docetaxel 80mg Injection is commonly prescribed for the specialized management of several distinct oncological conditions:

• Breast Cancer: It is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel 80mg Injection is also used as an adjuvant treatment for operable node-positive breast cancer in combination with doxorubicin and cyclophosphamide.
• Non-Small Cell Lung Cancer (NSCLC): The medication is a cornerstone therapy for patients with locally advanced or metastatic NSCLC after failure of prior platinum-based chemotherapy. It can also be used in combination with cisplatin for unresectable, locally advanced, or metastatic disease.
• Hormone-Refractory Prostate Cancer: Docetaxel 80mg Injection is the standard-of-care first-line chemotherapy, administered in combination with prednisone, for men with metastatic castration-resistant prostate cancer (mCRPC).
• Gastric Adenocarcinoma: In combination with cisplatin and fluorouracil, it is used for the treatment of patients with advanced gastric adenocarcinoma, including cancer of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.
• Head and Neck Cancer: Docetaxel 80mg Injection is utilized as part of an induction chemotherapy regimen for the treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Key Features

• Potent Microtubule Stabilization: The primary feature of Docetaxel 80mg Injection is its unique ability to hyper-stabilize microtubules, which is distinct from vinca alkaloids that prevent microtubule assembly, offering a complementary mechanism in oncology.
• High Intracellular Retention: The drug accumulates and remains within cancer cells for extended periods, ensuring a prolonged cytotoxic effect even after the infusion is complete.
• Standardized 80mg Potency: The 80mg vial strength is optimized for calculating body surface area (BSA)-based dosages, allowing for flexible and precise administration protocols in both monotherapy and combination regimens.
• Broad-Spectrum Efficacy: Docetaxel 80mg Injection has demonstrated clinical activity against a wide range of solid tumors, making it one of the most versatile agents in modern chemotherapy.
• Established Synergy: It is designed to work synergistically with other agents like trastuzumab or capecitabine, enhancing the overall therapeutic kill rate in resistant tumor models.

Storage for Docetaxel 80mg Injection

To preserve the pharmacological stability and ultimate potency of the taxane formulation, Docetaxel 80mg Injection must be stored with strict adherence to temperature guidelines. The vials should typically be stored between 2°C and 25°C (36°F to 77°F), although specific refrigeration (2°C to 8°C) requirements may vary by manufacturer; always check the specific package insert. It is vital to keep the medication in its original outer carton to protect the solution from bright light, which can degrade the active molecule. If the vial is a multi-dose formulation, it must be stored at 2°C to 8°C after the first puncture and used within 28 days. For maximum safety, store Docetaxel 80mg Injection in a secure, professional medical storage area that is strictly out of the reach and sight of children and unauthorized personnel.

Important Note on Docetaxel 80mg Injection

The administration of Docetaxel 80mg Injection requires comprehensive clinical management to mitigate severe side effects. Pre-medication is mandatory: Patients must receive an oral corticosteroid, such as dexamethasone, for 3 days starting 1 day prior to the infusion. This protocol is critical to reduce the severity of fluid retention (edema) and hypersensitivity reactions, which can manifest as severe rash, hypotension, or bronchospasm.

Docetaxel 80mg Injection carries a Boxed Warning for significant neutropenia (low white blood cell count); frequent complete blood counts (CBC) are required to monitor bone marrow function. Severe fluid retention, characterized by weight gain and swelling of the extremities or abdomen, can occur and may be irreversible in rare cases. Other common side effects include alopecia (hair loss), neuropathy (numbness in hands and feet), and fatigue. The drug is a vesicant/irritant; care must be taken to prevent extravasation (leakage into surrounding tissue) during intravenous administration, as this can cause tissue necrosis. Patients with hepatic impairment (liver problems) are at a higher risk of toxic death and generally should not receive this drug. By strictly following these professional guidelines and premedication protocols, healthcare providers can ensure that Docetaxel 80mg Injection provides the most effective relief and life-extending benefits for oncology patients.